Liphorus Pharmaceuticals Inc. is a pharmaceutical startup founded in 2014 with a mission to combat hypercholesterolemia through innovative PCSK9 targeting. The company has garnered attention with their pioneering compounds and has recently received a $6.40M Series A investment on 06 November 2014 from Sanderling Ventures and Univalor. Liphorus Pharmaceuticals is focused on developing small molecules that inhibit PCSK9, and has successfully secured a research collaboration with the IRCM to create and validate these PCSK9-targeting compounds. With such strong financial support and strategic partnerships, the company shows promise in revolutionizing the treatment of hypercholesterolemia within the pharmaceutical industry.
No recent news or press coverage available for Liphorus Pharmaceuticals Inc..